The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET

HQP8361 (MK8033) is a novel and selective MET kinase inhibitor that has completed a phase I clinical trial. AZD9291 (osimertinib) represents the first-approved third generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC) with activating EGFR muta...

Full description

Saved in:
Bibliographic Details
Published in:Am J Cancer Res
Main Authors: Yu, Danlei, Li, Yiting, Sun, Keven DY, Gu, Jiajia, Chen, Zhen, Owonikoko, Taofeek K, Ramalingam, Suresh S, Sun, Shi-Yong
Format: Artigo
Language:Inglês
Published: e-Century Publishing Corporation 2020
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7642664/
https://ncbi.nlm.nih.gov/pubmed/33163272
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items